BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17184146)

  • 21. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
    Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
    PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
    Fabbrini E; Mohammed BS; Korenblat KM; Magkos F; McCrea J; Patterson BW; Klein S
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2727-35. PubMed ID: 20371660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
    Park CW; Zhang Y; Zhang X; Wu J; Chen L; Cha DR; Su D; Hwang MT; Fan X; Davis L; Striker G; Zheng F; Breyer M; Guan Y
    Kidney Int; 2006 May; 69(9):1511-7. PubMed ID: 16672921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.
    Mráz M; Lacinová Z; Kaválková P; Haluzíková D; Trachta P; Drápalová J; Hanušová V; Haluzík M
    Physiol Res; 2011; 60(4):627-36. PubMed ID: 21574752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between four adipokines and insulin sensitivity in patients with obesity, type 1 or type 2 diabetes mellitus, and in the general Chinese population.
    Yuan T; Zhao WG; Sun Q; Fu Y; Dong YY; Dong YX; Yang GH; Wang H
    Chin Med J (Engl); 2010 Aug; 123(15):2018-22. PubMed ID: 20819535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
    Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
    Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
    J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report].
    Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A
    Przegl Lek; 2007; 64(2):70-3. PubMed ID: 17892035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
    Powell LA; Crowe P; Kankara C; McPeake J; McCance DR; Young IS; Trimble ER; McGinty A
    Clin Sci (Lond); 2012 Aug; 123(3):135-46. PubMed ID: 22309242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women.
    Anderlová K; Kremen J; Dolezalová R; Housová J; Haluzíková D; Kunesová M; Haluzík M
    Physiol Res; 2006; 55(3):277-283. PubMed ID: 16083306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
    Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
    Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
    Ryan KE; McCance DR; Powell L; McMahon R; Trimble ER
    Atherosclerosis; 2007 Oct; 194(2):e123-30. PubMed ID: 17145061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
    Winegar DA; Brown PJ; Wilkison WO; Lewis MC; Ott RJ; Tong WQ; Brown HR; Lehmann JM; Kliewer SA; Plunket KD; Way JM; Bodkin NL; Hansen BC
    J Lipid Res; 2001 Oct; 42(10):1543-51. PubMed ID: 11590209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.
    Guerre-Millo M; Gervois P; Raspé E; Madsen L; Poulain P; Derudas B; Herbert JM; Winegar DA; Willson TM; Fruchart JC; Berge RK; Staels B
    J Biol Chem; 2000 Jun; 275(22):16638-42. PubMed ID: 10828060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
    Cree MG; Zwetsloot JJ; Herndon DN; Qian T; Morio B; Fram R; Sanford AP; Aarsland A; Wolfe RR
    Ann Surg; 2007 Feb; 245(2):214-21. PubMed ID: 17245174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.